| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.14B | 1.04B | 2.85B | 416.00M | 1.94B | 1.79B |
| Short-term investments | 9.18B | 10.88B | 4.40B | 18.74B | 22.01B | 10.44B |
| Receivables | 11.87B | 11.46B | 11.57B | 10.95B | 11.48B | 7.91B |
| Inventory | 10.65B | 10.85B | 10.19B | 8.98B | 9.06B | 8.02B |
| Total current assets | 42.90B | 50.36B | 43.33B | 51.26B | 59.69B | 35.07B |
| Property, plant and equipment | 19.32B | 18.39B | 18.94B | 16.27B | 14.88B | 13.74B |
| Goodwill and intangibles | 125.00B | 123.94B | 132.68B | 94.75B | 74.35B | 77.89B |
| Total assets | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B | 154.23B |
| Accounts payable | 5.24B | 5.63B | 6.71B | 6.81B | 5.58B | 4.28B |
| Total current liabilities | 36.98B | 42.99B | 47.79B | 42.14B | 42.67B | 25.92B |
| Long-term debt | 61.64B | 57.41B | 61.54B | 32.88B | 36.20B | 37.13B |
| Total liabilities | 121.39B | 124.90B | 137.21B | 101.29B | 104.01B | 90.76B |
| Retained earnings | 114.61B | 116.72B | 118.35B | 125.66B | 103.39B | 90.39B |
| Shareholders' equity | 86.48B | 88.20B | 89.01B | 95.66B | 77.20B | 63.24B |
| Total debt | 64.80B | 66.80B | 79.85B | 35.83B | 38.44B | 40.39B |
| Net debt | 63.65B | 65.76B | 77.00B | 35.41B | 36.49B | 38.61B |
From Pfizer's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.